Troubled Canadian specialty pharma company Valeant has won U.S. approval for a new oral formulation of the previously injectable-only med Relistor for certain…

Zafgen fell about 40% in after-hours trading on news that it has suspended development of its lead obesity candidate beloranib, which had been on a clinical…

Buried deep down in Novartis’ Q2 results out this morning was a previously unknown rejection by the FDA for a copycat version of Amgen’s blockbuster drug…

One of AstraZeneca’s key drugs for its ambitious sales target Tagrisso (osimertinib) has hit its marks in a Phase III test for certain lung cancer patients--…

Another day, another unanimous FDA panel vote, this time recommending Novartis’ Enbrel (etanercept) biosimilar be approved across all of its U.S. licenses.

Kite Pharma has said it has no concerns with its recently enrolled experimental CAR-T trial that is using a chemo drug now dropped by rival Juno after it…

Amgen took one step closer to approval for its biosimilar of the world’s biggest-selling drug last night, but analysts don’t see it hitting the market this…

Juno Therapeutics was up by about 25% in after-hours trading on news that the FDA has already given it permission to resume the Phase II trial for its JCAR015…